Cancel

Links to sites outside of tumoti.com are provided as a resource to the audiences. Please note that Takeda is not responsible or liable for any third-party website and the website may not be appropriate for all audiences. 

To stay on the current website, select “Cancel”


Continue

You are leaving Takeda.com

Takeda - Global

EPD-3055 OneTrust Cookie

EPD-3519 Schema Script

EPD-2855 GTM Script

EPD-4037 Matomo Tag Manager

EPD-4268 Cookie Script Hack

Takeda provides annual and quarterly financial highlights, statements, and data for investors. Data are available to download in Excel format.

Financial Statements and Highlights | Takeda Investor Relations

Investor

# Financial Highlights



Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

## Sign up for our investors newsletter



**OSAKA, Japan and CAMBRIDGE, Massachusetts, May 14, 2024** – Takeda ([TSE: 4502/NYSE:TAK](http://mozqwq.tumoti.com/investors/overview/)) today announced that it will present data from its oncology pipeline and product portfolio at the [60th Annual Meeting of the American Society of Clinical Oncology (ASCO)](http://conferences.asco.org/am/attend) being held May 31-June 4, 2024, in Chicago, Ill.

Takeda’s presentations will span across a range of cancers, including colorectal, lung, lymphoma, multiple myeloma and leukemia and feature both clinical and real-world data generated to optimize treatment approaches and inform patient care. 

“At Takeda Oncology, we’re committed to addressing the areas of highest patient need while leveraging our expertise in key disease areas, including colorectal cancer, lung cancer and hematological malignancies,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit (OTAU) at Takeda. “Our presentations at ASCO, including data being presented in Hodgkin lymphoma and colorectal cancer, highlight the importance of combining our internal innovation with external partnerships to introduce new solutions and benefit the lives of people with cancer.” 

A full list of company-sponsored abstracts can be found [here](http://assets-dam.tumoti.com/image/upload/Takeda%2BOncology/siteassets/media/Takeda_Oncology_at_2024_ASCO_and_EHA/ASCO_2024_Abstract_Digital_5.7.pdf).

## Takeda’s Commitment to Oncology
At Takeda Oncology, we are united by our aspiration to cure cancer and motivated every day to work harder for patients with limited or ineffective treatment options. Our agile structure and deep in-house expertise are complemented by a network of partnerships that optimize our ability to research, develop and deliver transformative medicines to people living with cancer. Building on decades of leadership in oncology, we are focused on providing approved medicines for patients in need and advancing a cutting-edge oncology pipeline with the potential to introduce new therapies for people with solid tumors and hematologic cancers. With inspiration from patients and innovation from everywhere, we are committed to outsmarting cancer so that more patients can benefit from – and have access to – innovative medicines. For more information, visit [www.takedaoncology.com](http://www.takedaoncology.com).  

## About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit mozqwq.tumoti.com.

### Media Contacts:

#### Japanese Media

Jun Saito

[jun.saito@tumoti.com](mailto:jun.saito@tumoti.com )

#### U.S. and International Media

Sara Noonan

[sara.noonan@tumoti.com](mailto:sara.noonan@tumoti.com)

## Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

## Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: [http://mozqwq.tumoti.com/investors/sec-filings/](http://mozqwq.tumoti.com/investors/sec-filings/) or at [www.sec.gov](http://www.sec.gov). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

## Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


The EMA's CHMP has recommended approval of a potential treatment for patients with previously treated metastatic colorectal cancer. Learn more about what this could mean for patients in the EU.

Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting 

*   ***Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression***
*   ***AC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billion***
*   ***AC Immune to host conference call and webcast today at 8:30 a.m. ET***

**OSAKA, Japan, CAMBRIDGE, Massachusetts, and LAUSANNE, Switzerland, May 13, 2024** – Takeda ([TSE:4502/NYSE:TAK](http://mozqwq.tumoti.com/investors/overview/)) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.

ACI-24.060 is an anti-Abeta active immunotherapy candidate designed to induce a robust antibody response against the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s disease progression. By inducing plaque clearance and efficiently inhibiting plaque formation in the brain, ACI-24.060 has the potential to delay or slow Alzheimer’s disease progression. ACI-24.060 is being investigated in the ongoing ABATE randomized, double-blind, placebo-controlled Phase 1b/2 trial to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of the investigational immunotherapy in subjects with prodromal Alzheimer’s disease and in adults with Down syndrome.

“As pioneers in the field of active immunotherapy, we are developing an innovative approach that could change the treatment paradigm for Alzheimer’s disease and address the multifaceted burden that patients and the broader community face. We believe the maximum impact of ACI-24.060 can best be realized by partnering with Takeda at this critical juncture in its development, which will help us move rapidly into Phase 3,” said Dr. Andrea Pfeifer, CEO of AC Immune. “This agreement allows us to leverage the developmental expertise, strategic vision and financial capacity of an accomplished organization that has demonstrated its ability to execute the type of comprehensive global program required for Phase 3 trials in Alzheimer’s disease while allowing us to focus on completing Phase 1b/2 development and accelerating our efforts to replicate this success with enhanced funding for our early-stage pipeline.”

AC Immune will be responsible for completing the ABATE trial. Following option exercise, Takeda would conduct and fund all further clinical development and be responsible for all global regulatory activities as well as worldwide commercialization.

“At Takeda, we are committed to tackling some of society’s most debilitating illnesses, including Alzheimer’s disease. We are excited to partner with AC Immune on this ground-breaking treatment approach, which leverages novel technology with the potential to offer patients a treatment with differentiated efficacy, safety and ease of administration,” said Sarah Sheikh, M.Sc., B.M., B.Ch, MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda. “Combining AC Immune’s deep experience with active immunotherapy approaches with Takeda’s expertise in neuroscience drug development and commercialization, we have an incredible opportunity to deliver real impact to the Alzheimer’s community.”

Under the terms of the agreement, AC Immune will receive an upfront payment of $100 million and be eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1 billion if all related milestones are achieved over the course of the agreement. Upon commercialization, AC Immune will be entitled to receive tiered double-digit royalties on worldwide net sales.

Further details related to the agreement are available in the Form 6-K filed today by AC Immune with the U.S. Securities and Exchange Commission (SEC). The effectiveness of Takeda’s license following option exercise is subject to the termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act.

## Conference Call and Webcast Information

AC Immune management will host a conference call and webcast today at 8:30 a.m. ET to provide a brief overview of the agreement.

Monday, May 13 at 8:30 a.m. ET

Participants wishing to ask questions or to join the event via phone may call the following numbers 10 – 15 minutes before conference start:

<table><tr><td><strong>United States</strong></td><td>+1 (1) 631 570 56 13</td></tr><tr><td><strong>Switzerland / Europe</strong></td><td>+41 (0) 58 310 50 00</td></tr><tr><td><strong>United Kingdom</strong></td><td>+44 (0) 207 107 06 13</td></tr><tr><td>Other international numbers available</td><td><a href="http://services3.choruscall.ch/NUMBERS/Attended_Dial_In_Numbers.pdf">HERE</a></td></tr></table>

### Webcast:

[http://event.choruscall.com/mediaframe/webcast.html?webcastid=YteAZhdg](http://event.choruscall.com/mediaframe/webcast.html?webcastid=YteAZhdg)

Please note that there is a function to type in your questions via webcast.

A live and archived webcast will also be accessible in the Investors section of the Company's website at [http://www.acimmune.com/](http://www.acimmune.com/).

## About ACI-24.060

This product is AC Immune’s anti-Abeta active immunotherapy candidate. The ABATE randomized, double-blind, placebo-controlled Phase 1b/2 trial of ACI-24.060 for treatment of Alzheimer’s disease (AD) continues fully blinded ([NCT05462106](http://clinicaltrials.gov/study/NCT05462106?term=ACI-24.060\&rank=1)). Enrolled patients are required to have a diagnosis of prodromal AD: MCI due to AD according to the National Institute on Aging Alzheimer’s Association (NIA-AA) criteria, and a PET scan at screening must be consistent with the presence of amyloid pathology. Patients will be randomized to one of several doses of ACI-24.060 or placebo. Following multiple data safety monitoring board (DSMB) reviews, no safety concerns have been raised to date, consistent with previous results. Immunogenicity of the immunotherapy is very encouraging with clear evidence of anti-Abeta antibody responses against toxic Abeta species observed in the blinded data. The six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and the 12-month Abeta PET data are expected in Q4 2024.

## About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R\&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit [mozqwq.tumoti.com](http://mozqwq.tumoti.com/).

## About AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments.

SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

### AC Immune Investor and Media Contacts:

#### SVP, Investor Relations & Corporate Communications

Gary Waanders, Ph.D., MBA

AC Immune

Phone: +41 21 345 91 91

[gary.waanders@acimmune.com](mailto:gary.waanders@acimmune.com)

#### U.S. Investors

Corey Davis, Ph.D.

LifeSci Advisors

Phone: +1 212 915 2577

[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)

#### U.S. and International Media

Chris Maggos Cohesion Bureau

Phone: +41 79 367 6254

[chris.maggos@cohesionbureau.com](mailto:chris.maggos@cohesionbureau.com)

### Takeda Media Contacts:

#### Japanese Media

Yuko Yoneyama

[yuko.yoneyama@tumoti.com](mailto:yuko.yoneyama@tumoti.com)

+81 70-2610-6609

#### U.S. and International Media

Chris Stamm

[chris.stamm@tumoti.com](mailto:chris.stamm@tumoti.com)

+1 617-374-7726

## Takeda Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

## Takeda Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: [http://mozqwq.tumoti.com/investors/sec-filings-and-security-reports](http://mozqwq.tumoti.com/investors/sec-filings-and-security-reports) or at [www.sec.gov](http://www.sec.gov/). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

## AC Immune Forward Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward- looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.


Takeda and AC Immune partner for ACI-24.060, an active immunotherapy targeting toxic forms of amyloid beta to potentially slow Alzheimer’s disease progression. Learn more about this groundbreaking treatment approach and the agreement between Takeda and AC Immune.

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting  Amyloid Beta for Alzheimer’s Disease

Takeda Pharmaceutical Company Limited announced that the meeting of the Board of Directors held today resolved to continue the stock compensation plan which was introduced as a long-term incentive plan for members of the Board of Directors in 2016, as well as to continue the stock grant system which was introduced in 2014 as a global long-term incentive plan for Company Management in Japan. For the details, please see [here](http://assets-dam.tumoti.com/image/upload/v1715219662/Global/Investor/Financial-Results/FY2023/Q4/eng-press-release-fy24-bip-esop-trust-creation-updated.pdf).


Takeda today announced that the meeting of the Board of Directors held today resolved to continue the stock compensation plan for members of the Board of Directors. 

Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2024

OSAKA, Japan, May 9, 2024 – Takeda ([TSE:4502/NYSE:TAK](http://mozqwq.tumoti.com/investors/stock-information/) ) today announced financial results for fiscal year 2023 (period ended March 31, 2024). Takeda delivered its Management Guidance for Core Operating Profit and exceeded its Management Guidance for Revenue and Core EPS performance at CER. For details, please see [here](http://assets-dam.tumoti.com/image/upload/v1715231595/Global/Investor/Financial-Results/FY2023/Q4/q4_fy2023_press_release_en.pdf).


OSAKA, Japan, May 9, 2024 – Takeda (TSE:4502/NYSE:TAK ) today announced financial results for fiscal year 2023 (period ended March 31, 2024). Takeda delivered its Management Guidance for Core Operating Profit and exceeded its Management Guidance for Revenue and Core EPS performance at CER. For details, please see here.

Takeda Announces FY2023 Full-year Results and FY2024 Outlook; Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion